Disclosures

The authors have no financial conflicts of interest.

References

1. Macpherson, A. J., K. D. McCoy, F. E. Johansen, and P. Brandtzaeg. 2008. The immune geography of IgA induction and function. *Mucosal Immunol.* 1: 11–22.
2. Woof, J. M., and M. A. Kerr. 2006. The function of immunoglobulin A in immunity. *J. Pathol.* 208: 270–282.
3. Kunisawa, J., Y. Kurashima, and H. Kiyono. 2012. Gut-associated lymphoid tissues for the development of oral vaccines. *Adv. Drug Deliv. Rev.* 64: 523–530.
4. Fagarasan, S., S. Kawamoto, O. Kanagawa, and K. Suzuki. 2010. Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis. *Annu. Rev. Immunol.* 28: 243–273.
5. Cerutti, A., K. Chen, and A. Chorny. 2011. Immunoglobulin responses at the mucosal interface. *Annu. Rev. Immunol.* 29: 273–293.
6. Spencer, S. P., and Y. Belkaid. 2012. Dietary and commensal derived nutrients: shaping mucosal and systemic immunity. *Curr. Opin. Immunol.* 24: 379–384.
7. Weinstein, P. D., and J. J. Cebra. 1991. The preference for switching to IgA expression by Peyer's patch germinal center B cells is likely due to the intrinsic influence of their microenvironment. *J. Immunol.* 147: 4126–4135.
8. Hamada, H., T. Hiroi, Y. Nishiyama, H. Takahashi, Y. Masunaga, S. Hachimura, S. Kaminogawa, H. Takahashi-Iwanaga, T. Iwanaga, H. Kiyono, et al. 2002. Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine. *J. Immunol.* 168: 57–64.
9. Kunisawa, J., M. Gohda, E. Hashimoto, I. Ishikawa, M. Higuchi, Y. Suzuki, Y. Goto, C. Panea, and I.I. Ivanov, R. Sumiya, et al. 2013. Microbe-dependent CD11b$^+$ IgA$^+$ plasma cells mediate robust early-phase intestinal IgA responses in mice. *Nat. Commun.* 4: 1772.
10. Maslowski, K. M., and C. R. Mackay. 2011. Diet, gut microbiota and immune responses. *Nat. Immunol.* 12: 5–9.
11. Kunisawa, J., and H. Kiyono. 2013. Vitamin-mediated regulation of intestinal immunity. *Front. Immunol.* 4: 189.
12. Hanson, L. A., A.-K. Robertson, J. Bjersing, and M. V. Herias. 2005. Undernutrition, immunodeficiency, and mucosal infections. In *Mucosal Immunology*, 3rd ed. J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstock, J. R. McGhee, and L. Mayer, eds. Academic Press, San Diego, CA, p. 1159–1178.
13. Wintergerst, E. S., S. Maggini, and D. H. Hornig. 2007. Contribution of selected vitamins and trace elements to immune function. *Ann. Nutr. Metab.* 51: 301–323.
14. Galli, C., and P. C. Calder. 2009. Effects of fat and fatty acid intake on inflammatory and immune responses: a critical review. *Ann. Nutr. Metab.* 55: 123–139.
15. Margioris, A. N. 2009. Fatty acids and postprandial inflammation. *Curr. Opin. Clin. Nutr. Metab. Care* 12: 129–137.
16. Arita, M. 2012. Mediator lipidomics in acute inflammation and resolution. *J. Biochem.* 152: 313–319.
17. Jin, C., and R. A. Flavell. 2013. Innate sensors of pathogen and stress: linking inflammation to obesity. *J. Allergy Clin. Immunol.* 132: 287–294.
18. Schmitz, G., and J. Ecker. 2008. The opposing effects of n-3 and n-6 fatty acids. *Prog. Lipid Res.* 47: 147–155.
19. Nguyen, M. T., S. Favelyukis, A. K. Nguyen, D. Reichart, P. A. Scott, A. Jenn, R. Liu-Bryan, C. K. Glass, J. G. Neels, and J. M. Olefsky. 2007. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. *J. Biol. Chem.* 282: 35279–35292.
20. Håversen, L., K. N. Danielsson, L. Fogelstrand, and O. Wiklund. 2009. Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages. *Atherosclerosis* 202: 382–393.
21. He, Q., R. T. Riley, and R. P. Sharma. 2005. Myriocin prevents fumonisin B1-induced sphingoid base accumulation in mice liver without ameliorating hepatotoxicity. *Food Chem. Toxicol.* 43: 969–979.
22. Gohda, M., J. Kunisawa, F. Miura, Y. Kagiyama, Y. Kurashima, M. Higuchi, I. Ishikawa, I. Ogahara, and H. Kiyono. 2008. Sphingosine 1-phosphate regulates the egress of IgA plasmablasts from Peyer's patches for intestinal IgA responses. *J. Immunol.* 180: 5335–5343.
23. Schaeffler, A., P. Gross, R. Buettner, C. Bollheimer, C. Buechler, M. Neumeier, A. Kopp, J. Schoelmerich, and W. Falk. 2009. Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity. *Immunology* 126: 233–245.
24. Maloney, E., I. R. Sweet, D. M. Hockenbery, M. Pham, N. O. Rizzo, S. Tateya, P. Handa, M. W. Schwartz, and F. Kim. 2009. Activation of NF-kappaB by palmitate in endothelial cells: a key role for NADPH oxidase-derived superoxide in response to TLR4 activation. *Arterioscler. Thromb. Vasc. Biol.* 29: 1370–1375.
25. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. *Science* 282: 2085–2088.
26. Hoshino, K., O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa, Y. Takeda, K. Takeda, and S. Akira. 1999. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. *J. Immunol.* 162: 3749–3752.
27. Fyrst, H., and J. D. Saba. 2010. An update on sphingosine-1-phosphate and other sphingolipid mediators. *Nat. Chem. Biol.* 6: 489–497.
28. Hannun, Y. A., and L. M. Obeid. 2008. Principles of bioactive lipid signalling: lessons from sphingolipids. *Nat. Rev. Mol. Cell Biol.* 9: 139–150.
29. Kayama, H., and K. Takeda. 2012. Regulation of intestinal homeostasis by innate and adaptive immunity. *Int. Immunol.* 24: 673–680.
30. Kennedy, A., K. Martinez, C. C. Chuang, K. LaPoint, and M. McIntosh. 2009. Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: mechanisms of action and implications. *J. Nutr.* 139: 1–4.
31. Weigert, C., K. Brodbeck, H. Staiger, C. Kausch, F. Machicao, H. U. Häring, and E. D. Schleicher. 2004. Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor-kappaB. *J. Biol. Chem.* 279: 23942–23952.
32. Weatherill, A. R., J. Y. Lee, L. Zhao, D. G. Lemay, H. S. Youn, and D. H. Hwang. 2005. Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. *J. Immunol.* 174: 5390–5397.
33. Snodgrass, R. G., S. Huang, I. W. Choi, J. C. Rutledge, and D. H. Hwang. 2013. Inflammasome-mediated secretion of IL-1β in human monocytes through TLR2 activation; modulation by dietary fatty acids. *J. Immunol.* 191: 4337–4347.
34. Zhao, L., M. J. Kwon, S. Huang, J. Y. Lee, K. Fukase, N. Inohara, and D. H. Hwang. 2007. Differential modulation of Nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells. *J. Biol. Chem.* 282: 11618–11628.
35. Erridge, C., and N. J. Samani. 2009. Saturated fatty acids do not directly stimulate Toll-like receptor signaling. *Arterioscler. Thromb. Vasc. Biol.* 29: 1944–1949.
36. Schwartz, E. A., W. Y. Zhang, S. K. Karnik, S. Borwege, V. R. Anand, P. S. Laine, Y. Su, and P. D. Reaven. 2010. Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. *Arterioscler. Thromb. Vasc. Biol.* 30: 802–808.
37. Merrill, A. H., Jr. 1983. Characterization of serine palmitoyltransferase activity in Chinese hamster ovary cells. *Biochim. Biophys. Acta* 754: 284–291.
38. Gault, C. R., L. M. Obeid, and Y. A. Hannun. 2010. An overview of sphingolipid metabolism: from synthesis to breakdown. *Adv. Exp. Med. Biol.* 688: 1–23.
39. Cyster, J. G., and S. R. Schwab. 2012. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. *Annu. Rev. Immunol.* 30: 69–94.
40. Kunisawa, J., Y. Kurashima, M. Gohda, M. Higuchi, I. Ishikawa, F. Miura, I. Ogahara, and H. Kiyono. 2007. Sphingosine 1-phosphate regulates peritoneal B-cell trafficking for subsequent intestinal IgA production. *Blood* 109: 3749–3756.
41. Bouhours, D., and J. F. Bouhours. 1985. Developmental changes of monohexosylceramide and free ceramide in the large intestine of the rat. *J. Biochem.* 98: 1359–1366.
42. Gustafsson, B. E., K. A. Karlsson, G. Larson, T. Midtvedt, N. Strömberg, S. Teneberg, and J. Thurin. 1986. Glycosphingolipid patterns of the gastrointestinal tract and feces of germ-free and conventional rats. *J. Biol. Chem.* 261: 15294–15300.
43. Kishino, S., M. Takeuchi, S. B. Park, A. Hirata, N. Kitamura, J. Kunisawa, H. Kiyono, R. Iwamoto, Y. Isobe, M. Arita, et al. 2013. Polyunsaturated fatty acid saturation by gut lactic acid bacteria affecting host lipid composition. *Proc. Natl. Acad. Sci. USA* 110: 17808–17813.
44. Duan, R. D., L. Nyberg, and A. Nilsson. 1995. Alkaline sphingomyelinase activity in rat gastrointestinal tract: distribution and characteristics. *Biochim. Biophys. Acta* 1259: 49–55.
45. Kono, M., J. L. Dreier, J. M. Ellis, M. L. Allende, D. N. Kalkofen, K. M. Sanders, J. Bielawski, A. Bielawska, Y. A. Hannun, and R. L. Proia. 2006. Neutral ceramidase encoded by the Asah2 gene is essential for the intestinal degradation of sphingolipids. *J. Biol. Chem.* 281: 7324–7331.

CellPress

Immunity
Article

Dectin-2 Is a Direct Receptor for Mannose-Capped Lipoarabinomannan of Mycobacteria

Akiko Yonekawa,[1,2,9] Shinobu Saijo,[3,4,9] Yoshihiko Hoshino,[5] Yasunobu Miyake,[1] Eri Ishikawa,[1] Maho Suzukawa,[6] Hiromasa Inoue,[7] Masato Tanaka,[8] Mitsutoshi Yoneyama,[3] Masatsugu Oh-hora,[1,4] Koichi Akashi,[2] and Sho Yamasaki[1,3,*]
[1]Division of Molecular Immunology, Medical Institute of Bioregulation
[2]Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences
Kyushu University, Fukuoka 812-8582, Japan
[3]Division of Molecular Immunology, Medical Mycology Research Center, Chiba University, Chiba 260-8673, Japan
[4]PRESTO, Japan Science and Technology Agency (JST), Saitama 332-0012, Japan
[5]Leprosy Research Center, National Institute of Infectious Diseases, Tokyo 189-0002, Japan
[6]Center for Pulmonary Diseases, National Hospital Organization, Tokyo National Hospital, Tokyo 204-8585, Japan
[7]Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan
[8]Laboratory for Immune Regulation, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan
[9]Co-first author
*Correspondence: yamasaki@bioreg.kyushu-u.ac.jp
http://dx.doi.org/10.1016/j.immuni.2014.08.005

SUMMARY

Mycobacteria possess various immunomodulatory molecules on the cell wall. Mannose-capped lipoarabinomannan (Man-LAM), a major lipoglycan of *Mycobacterium tuberculosis*, has long been known to have both inhibitory and stimulatory effects on host immunity. However, the direct Man-LAM receptor that explains its pleiotropic activities has not been clearly identified. Here, we report that a C-type lectin receptor Dectin-2 (gene symbol *Clec4n*) is a direct receptor for Man-LAM. Man-LAM activated bone-marrow-derived dendritic cells (BMDCs) to produce pro- and anti-inflammatory cytokines, whereas it was completely abrogated in *Clec4n*$^{-/-}$ BMDCs. Man-LAM promoted antigen-specific T cell responses through Dectin-2 on DCs. Furthermore, Man-LAM induced experimental autoimmune encephalitis (EAE) as an adjuvant in mice, whereas *Clec4n*$^{-/-}$ mice were resistant. Upon mycobacterial infection, *Clec4n*$^{-/-}$ mice showed augmented lung pathology. These results demonstrate that Dectin-2 contributes to host immunity against mycobacterial infection through the recognition of Man-LAM.

INTRODUCTION

Mycobacteria possess various cell wall components that influence host immune responses, such as trehalose-6,6′-dimycolate (TDM), mycolate, phosphatidyl-*myo*-inositol mannosides (PIMs), lipomannnan (LM), and lipoarabinomannan (LAM). LAM is a major lipoglycan and important virulence factor of mycobacteria (Mishra et al., 2011), enabling mycobacteria to infect host organisms and survive within host cells. Ethambutol, an inhibitor of LAM synthesis, is widely used as an antimycobacterial drug (Belanger et al., 1996). LAM consists of four components: a mannosyl-phosphatidyl-*myo*-inositol (MPI) anchor, a mannose backbone, an arabinan domain, and capping moieties. The capping moieties located at the terminal extremity of the arabinan domain differ among mycobacterial species, such as mannose-capped LAM (Man-LAM), phosphoinositol-capped LAM (PI-LAM), and noncapped LAM (Ara-LAM). Among them, Man-LAM has been intensively studied because it exerts pleiotropic effects on host immunity (Mishra et al., 2011).

Pathogenic species, including *Mycobacterium tuberculosis*, possess Man-LAM, which has been shown to suppress host immune system (Briken et al., 2004) and phagosome-lysosome fusion (Fratti et al., 2003). Although various inhibitory mechanisms have been proposed thus far, one of the key events is the production of immunosuppressive cytokine interleukin-10 (IL-10). On the other hand, Man-LAM also potentiates immunostimulatory responses, such as nitric oxide release and secretion of proinflammatory cytokines (Chan et al., 2001; Gringhuis et al., 2009; Mazurek et al., 2012).

C-type lectin receptors (CLRs) have been recently identified as pattern recognition receptors (PRRs) for a wide variety of pathogens. A member of CLRs, dendritic-cell (DC)-specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN, also called CD209) and its putative murine homologs SIGN-related 1 (SIGNR1, also called CD209b) and SIGNR3 (CD209d) are reported to recognize Man-LAM and mediate its immunosuppressive activities (Geijtenbeek et al., 2003; Schlesinger et al., 1994; Tailleux et al., 2003). Macrophage mannose receptor (MMR, also called CD206) is also a candidate for inhibitory receptor for LAM, because it delivers a negative signal to attenuate DC activation (Nigou et al., 2001). In addition to these reports regarding inhibitory functions, engagement of SIGNR3 by Man-LAM also induces the secretion of IL-6 and tumor necrosis factor (TNF) in macrophages transfected with SIGNR3 (Tanne et al., 2009). Moreover, the scavenger receptor CD36 enhances the stimulatory activity of Man-LAM leading to TNF release in lipopolysaccharide (LPS)-stimulated macrophage cell line (Józefowski et al., 2011). Although many proteins have been proposed as a receptor for Man-LAM, none of these receptors fully explain its divergent functions, both stimulatory and inhibitory effects,

CrossMark



Figure 1. LAM Induces EAE through FcRγ Axis
(A and B) WT (n = 4) and $Fcer1g^{-/-}$ (n = 4) mice were immunized with MOG_{35-55} peptide in IFA containing LAM (500 μg), followed by i.p. injection of PT (500 ng) (day 1, 2, and 3). The disease severity of each mouse was scored, and mean clinical score (A) and disease incidence (B) at the indicated times were plotted.
(C and D) Lumbar (C) and inguinal (D) lymph nodes were collected at 23 days after immunization. Lymph node cells were stimulated with MOG_{35-55} peptide for 4 days. Concentrations of IL-17, IFN-γ, and GM-CSF were determined with ELISA.
(E and F) BMDCs obtained from WT, $Clec4e^{-/-}$, $Fcer1g^{-/-}$, or $MyD88^{-/-}$ mice were stimulated with plate-coated LAM (0.3 μg/well) or LPS (10 ng/ml) for 48 hr. The concentrations of MIP-2 (E) and TNF (F) were measured using ELISA.
(A–D) Data are representative of two separate experiments.
(E and F) All data are presented as the means ± SD of triplicate and are representative of three separate experiments.
See also Figure S1.

suggesting the possibility that unidentified molecules act as receptors for Man-LAM.

We recently demonstrated that CLRs Mincle (gene symbol *Clec4e*) and MCL (gene symbol *Clec4d*) are Fc receptor γ chain (FcRγ, gene symbol *Fcer1g*)-coupled activating receptors for mycobacterial glycolipids (Ishikawa et al., 2009; Miyake et al., 2013). Another CLR, DC-associated C-type lectin-2 (Dectin-2, gene symbol *Clec4n*), is located adjacent to Mincle and MCL within the gene cluster on chromosome 6. Dectin-2 is an FcRγ-coupled CLR (Sato et al., 2006) that recognizes *Candida albicans* hyphae to mediate host defense against the fungus (Robinson et al., 2009; Saijo et al., 2010). Dectin-2 and MCL seem to have arisen by gene duplication from Mincle after placentalia and are well conserved among species (Miyake et al., 2013). These findings imply that these CLRs within the gene cluster might have evolved as "mycobacterial receptors" and that Dectin-2 might also recognize mycobacteria.

In this study, we show that Dectin-2 is a direct receptor for Man-LAM. Man-LAM recognition by Dectin-2 induced the production of both pro- and anti-inflammatory cytokines in DCs. Man-LAM potently promoted T-cell-mediated acquired immunity as an adjuvant without causing detrimental inflammation. We further demonstrate, through Dectin-2-deficient mice, that Dectin-2 plays a critical role in host responses against mycobacterial infection. Collectively, these findings indicate that Dectin-2 acts as a functional PRR for mycobacterial Man-LAM.

RESULTS

LAM Promotes Experimental Autoimmune Encephalomyelitis through FcRγ

We first investigated whether LAM possess adjuvant activity in vivo. To this end, we performed a murine model of T-cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis (EAE) (Figures 1A–1D). Mice were immunized with myelin oligodendrocyte glycoprotein (MOG) peptide together with LAM derived from virulent *M. tuberculosis* strain Aoyama B. Although EAE was not induced by incomplete Freund's adjuvant (IFA) alone (data not shown), a single injection of LAM elicited EAE with 100% incidence (Figures 1A and 1B). The EAE symptoms were completely abrogated in $Fcer1g^{-/-}$ mice (Figures 1A and 1B), suggesting that FcRγ-coupled receptor(s) might contribute to LAM-induced EAE. Furthermore, in contrast to lymphocytes from wild-type mice, lymphocytes from $Fcer1g^{-/-}$ mice exhibited impaired ex vivo recall responses to MOG peptides as judged by the production of IL-17, interferon-γ (IFN-γ), and granulocyte macrophage-colony stimulating factor (GM-CSF) (Figures 1C and 1D). These results indicate that LAM could act as a potent adjuvant leading to the development of EAE through an FcRγ-dependent pathway.

Because FcRγ is mainly expressed in myeloid cells, we next treated DCs with LAM in vitro. To recapitulate uniform configuration and multivalency of LAM on the bacterial wall, LAM was coated on culture plate for the stimulation of bone-marrow-derived DCs (BMDCs). Although soluble LAM did not induce cytokine production (data not shown), plate-coated LAM could stimulate BMDCs to secrete a large amount of the proinflammatory cytokines, macrophage inflammatory protein-2 (MIP-2), and



Figure 2. Dectin-2 Recognizes Pathogenic Mycobacterial Species though LAM

(A) NFAT-GFP reporter cells expressing Mincle + FcRγ (Mincle) or Dectin-2 + FcRγ (Dectin-2) were stimulated with heat-killed *M. tuberculosis* H37Rv or *M. bovis* BCG. TDM and *Candida albicans* cell wall mannan were used in plate-coated form as a positive control.

(B) Reporter cells were stimulated with plate-coated water extract or C:M extract for 24 hr.

(C) Reporter cells expressing FcRγ alone or Dectin-2 + FcRγ were stimulated with the indicated amounts of LAM derived from *M. tuberculosis* strain Aoyama B in plate-coated form for 24 hr.

Induction of NFAT-GFP was analyzed using flow cytometry. All data are presented as the means ± SD of triplicate assays and representative results from three independent experiments with similar results are shown. See also Figure S2.

TNF (Figures 1E and 1F). These cytokines were still produced in *Clec4e*$^{-/-}$ (Figures 1E and 1F) and *Clec4d*$^{-/-}$ (data not shown) DCs. MyD88 was dispensable for this response, indicating that toll-like receptors (TLRs) do not play major role in LAM recognition. In contrast, LAM-induced cytokine production was abrogated in *Fcer1g*$^{-/-}$ DCs. These results suggest that some unknown FcRγ-coupled receptor(s) might function as an activating receptor for LAM in BMDCs.

Dectin-2 Recognizes Mycobacterial LAM

Mincle, MCL, and Dectin-2 are FcRγ-coupled activating receptors within the same gene cluster, and two of these receptors, Mincle and MCL, recognize mycobacteria (Ishikawa et al., 2009; Miyake et al., 2013). We therefore assumed that Dectin-2 might also be evolved as a receptor for mycobacteria. Indeed, Dectin-2 was demonstrated to recognize the virulent strain *M. tuberculosis* H37Rv and the vaccine strain *M. bovis* Bacille de Calmette et Guérin (BCG) to activate the reporter cells, in a similar manner to Mincle (Figure 2A). However, the ligand for Dectin-2 was distinct from Mincle ligand trehalose-6,6′-dimycolate (TDM) (Figure 2A).

We next fractionated components of *M. bovis* BCG using lipophilic and hydrophilic solvents, such as chloroform:methanol (C:M) and water. The Dectin-2 ligand activity for each of the extracts was assessed in a plate-coated form using reporter cells. We found that only the water phase demonstrated a stimulatory activity for Dectin-2 (Figure 2B, right), in sharp contrast to the C:M phase that activates Mincle-expressing cells (Figure 2B, left) (Ishikawa et al., 2009). These results suggest that the hydrophilic components of mycobacteria are candidates for the Dectin-2 ligand. Among mycobacterial hydrophilic components, LAM constitutes the most abundant hydrophilic lipoglycan (Figure S1 available online; Leopold and Fischer, 1993). In agreement with our prediction, LAM derived from *M. tuberculosis* activated reporter cells expressing Dectin-2 (Figure 2C). Dectin-2 directly recognized the LAM, as shown by the fact that soluble Dectin-2 protein (Dectin-2-Ig) bound to purified LAM in a dose-dependent manner (Figure S2). These findings indicate that Dectin-2 is a direct receptor for mycobacterial LAM.

Dectin-2 Recognizes Mycobacteria through Mannose-Capped LAM

The structure of LAM differs depending on the mycobacterial species, particularly with the respect to the capping moieties (Briken et al., 2004). The slow-growing strains including *M. tuberculosis* and *M. bovis* BCG possess Man-LAM, whereas rapid-growing strains of mycobacteria do not. *M. smegmatis* possesses PI-LAM. To clarify which structure of LAM is responsible for the interaction with Dectin-2, we used various strains of mycobacteria including nontuberculosis mycobacteria (NTM).

Dectin-2 recognized slow-growing strains, such as *M. intracellulare* and *M. gordonae*, which possess Man-LAM. In contrast, Dectin-2 did not recognize *M. abscessus* and *M. smegmatis* that lack mannose capping (Figure 3A). Importantly, Mincle was capable of recognizing these strains (Figure 3A). We confirmed that none of these strains activated reporter cells expressing FcRγ alone (data not shown). These results suggest that Dectin-2 preferentially recognizes the mycobacterial species that express Man-LAM. Supporting this notion, the activity of Man-LAM derived from *M. tuberculosis* (Figure 2C) was abolished by treatment with α-mannosidase that removes terminal mannose caps (Figure 3B). These results indicate that the capping structures are crucial determinants for the recognition of Man-LAM by Dectin-2.

We next investigated whether the mannose binding capacity of Dectin-2 is involved in Man-LAM recognition. To this end, we employed the Dectin-2^{QPD} mutant in which the mannose-binding activity was eliminated by substituting EPN (glutamic acid-proline-asparagine) sequence into galactose-type QPD (glutamine-proline-asparagic acid) sequence (Drickamer,





Figure 3. Dectin-2 Selectively Recognizes Mannose-Capped LAM

(A) NFAT-GFP reporter cells expressing Mincle + FcRγ or Dectin-2 + FcRγ were stimulated with the indicated strains of heat-killed NTM.

(B) Reporter cells expressing Dectin-2 + FcRγ were stimulated with *M. bovis* BCG pretreated with or without α-mannosidase for 24 hr.

(C and D) Reporter cells expressing Dectin-2^{WT} + FcRγ or Dectin-2^{QPD} + FcRγ were stimulated with plate-coated LAM (C) and NTM strains (D) for 24 hr.

All data are presented as the means ± SD of triplicate and are representative of three separate experiments. See also Figure S3.

1992; Ishikawa et al., 2013). Man-LAM did not activate reporter cells expressing Dectin-2^{QPD} (Figure 3C) regardless of similar fluorescence intensities of wild-type Dectin-2 and Dectin-2^{QPD} on the cell surface (Figure S3). The recognition of whole mycobacteria by Dectin-2 was also dependent on this EPN motif (Figure 3D). Collectively, these results indicate that both mannose caps of Man-LAM and mannose-recognition property of Dectin-2 are required for the interaction of Man-LAM with Dectin-2.

Man-LAM Induces Cytokine Production by DCs in a Dectin-2-Dependent Manner

Among the myeloid cells, DCs most abundantly express Dectin-2 (Ariizumi et al., 2000). We therefore investigated the cytokine production in response to Man-LAM in BMDCs. Man-LAM, similar to TDM, induced the expression of inflammatory cytokines, such as MIP-2, TNF, and IL-6, in a dose-dependent manner (Figure 4A). The LAM-induced cytokine production was abolished in *Clec4n*$^{-/-}$ BMDCs, whereas the TDM-mediated cytokine production was not altered (Figure 4A). Man-LAM also slightly enhanced IL-12p40 in a Dectin-2-dependent manner (data not shown). The production of TNF and IL-6 upon *M. bovis* BCG infection was partially decreased in *Clec4n*$^{-/-}$ BMDCs as compared with WT BMDCs, although there remained Dectin-2-independent cytokine production (Figure 4B). These data indicate that Dectin-2 is critical for Man-LAM-mediated proinflammatory cytokine production in DCs.

We next focused on the anti-inflammatory potential of Man-LAM-Dectin-2 pathway, due to the fact that accumulating evidence has emphasized the importance of the immune-suppressive action of Man-LAM (Geijtenbeek et al., 2003; Wieland et al., 2007). In addition to proinflammatory cytokines, Man-LAM potently induced the production of anti-inflammatory cytokine, IL-10, in BMDCs (Figure 4C, left). Other pathogen-associated molecular patterns (PAMPs), TDM (Figure 4C, right) and LPS (data not shown), did not induce the secretion of IL-10 and IL-2, indicating that Man-LAM has a unique profile of the cytokine production. Man-LAM-induced release of these cytokines was completely suppressed in *Clec4n*$^{-/-}$ BMDCs (Figure 4C). Although TNF production during *M. bovis* BCG infection was partially dependent on Dectin-2 as described above (Figure 4B), the production of IL-10 and IL-2 was almost completely lost in *Clec4n*$^{-/-}$ DCs infected with *M. bovis* BCG (Figure 4D). Meanwhile, *M. abscessus*, which is absent from mannose caps, failed to induce the production of IL-10 and IL-2, compared to the capability of MIP-2 production (Figure 4E). These results suggest a central role of Dectin-2 in the production of IL-10 and IL-2 in response to mycobacteria.

Dectin-2-Mediated Intrinsic Signal Regulates Man-LAM-Induced Cytokine Production in DCs

It is clear that Dectin-2 is required for the cytokine production induced by Man-LAM, because such production is abrogated in *Clec4n*$^{-/-}$ cells (Figures 4A and 4C). However, it is still



Figure 4. LAM Induces Cytokine Production in a Dectin-2-Dependent Manner

(A–D) BMDCs obtained from WT or *Clec4n*$^{-/-}$ mice were stimulated with the indicated amounts of plate-coated LAM or TDM for 48 hr (A and C). BMDCs were infected with 1 to 10 × 10^9 of *M. bovis* BCG for 48 hr (B and D). LPS was used as control. The concentrations of MIP-2, TNF, IL-6 (A and B), IL-10, and IL-2 (C and D) were measured using ELISA.

(E) BMDCs were stimulated for 48 hr with *M. bovis* BCG or clinical isolates of heat-killed *M. abscessus* derived from ten individual patients. The concentrations of MIP-2, IL-10, and IL-2 were measured using ELISA.

All data are presented as the means ± SD of triplicate and are representative of three separate experiments. See also Figure S4.

uncertain whether the Dectin-2-mediated intrinsic signal is sufficient or whether some other coreceptor is also required for these responses. The unique cytokine profiles, particularly IL-10 and IL-2 production, may be conferred by the coengagement of Dectin-2 and other Man-LAM receptors. To examine this possibility, we investigated the contribution of several candidate receptors for Man-LAM. Since SIGNR1, a putative murine homolog of human DC-SIGN, recognizes Man-LAM (Koppel et al., 2004), we evaluated the role of SIGNR1 by establishing SIGNR1-deficient mice (Figure S4A). However, BMDCs lacking SIGNR1 were still capable of producing all cytokines tested at amounts comparable to those in WT BMDCs (Figure S4B). Another DC-SIGN homolog, SIGNR3, which is expressed in a limited population of myeloid cells (Nagaoka et al., 2010), was not detected in BMDCs (Figure S4C). Furthermore, forced expression of SIGNR3 in BMDCs did not increase Man-LAM-induced cytokine production (Figure S4D). Notably, *Clec4n*$^{-/-}$ BMDCs failed to produce cytokines even with the expression of SIGNR3 (Figure S4D). These results collectively indicate that both SIGNR1 and SIGNR3 are not essential for cytokine production induced by Man-LAM in BMDCs.

Macrophage mannose receptor (MMR) could also bind to Man-LAM (Nigou et al., 2001). Because MMR expression was detected in BMDCs (Figure S4C), we assessed its role in Man-LAM-induced cytokine release by using anti-MMR blocking monoclonal antibody (mAb). However, the mAb treatment did not influence the production of IL-10 and IL-2 in BMDCs (Figure S4E).

A recent report has shown that Dectin-2 is capable of associating with MCL (Zhu et al., 2013). Meanwhile, analyses of *Clec4d*$^{-/-}$ BMDCs revealed that MCL is not required for the Man-LAM-induced cytokine production (Figure S4F). Man-LAM is weakly recognized by TLR2 and TLR4 (Mazurek et al., 2012). However, IL-10 production induced by Man-LAM was not altered in *MyD88*$^{-/-}$ BMDCs (Figure S4G), suggesting that TLR-MyD88 signaling does not play a major role in the effect of Man-LAM. Finally, we confirmed that the direct engagement of Dectin-2 alone by anti-Dectin-2 cross-linking replicated the production of IL-10 (Figure S4H).





Figure 5. LAM Does Not Cause Excessive Inflammation in the Lungs

(A and B) Mice were intratracheally administered 100 μg of LAM (WT, n = 13; *Fcer1g*$^{-/-}$, n = 5), 10 μg of LPS (WT, n = 9), or 100 μl of sterile saline as a control (WT, n = 7). After 8 hr, BALF was obtained and then TNF concentrations in the BALF were determined using ELISA (A). The number of total cells was determined by hemocytometer (B). All data are presented as the means ± SD.

(C) Lungs of control mice (Cont., n = 11), 50 μg of LAM (LAM, n = 11)- or 50 μg of TDM (TDM, n = 7)-injected mice were isolated at day 7 and inflammatory intensity was evaluated by calculation of lung weight index. Each symbol represents an individual mouse. Data are representative of three separate experiments.

(D) Histology of the lungs from control, LAM (50 μg)-, or TDM (50 μg)-injected mice were was examined by hematoxylin-eosin staining at day 7. Scale bars represent 0.1 mm. Data are representative of three separate experiments.

Collectively, these results suggest that the IL-10-inducing potential of Man-LAM is likely due to the intrinsic properties of Dectin-2-mediated signaling.

Man-LAM Induces Minimal Inflammation In Vivo

To investigate whether Man-LAM triggers any inflammatory responses, we evaluated the response of mice to Man-LAM administration in vivo. The infiltration of inflammatory cells and cytokine production in bronchoalveolar lavage fluid (BALF) was examined following the intratracheal administration of LAM or LPS (Figures 5A and 5B). LPS induced a significant increase in TNF production and cell infiltration in WT mice. In contrast, Man-LAM did not induce marked inflammatory responses. Consistent with this observation, FcRγ deficiency had no apparent effect compared with Man-LAM-treated WT mice.

Intravenous injection of TDM induced inflammatory lung swelling as assessed by lung weight index (LWI) (Figure 5C) and granuloma formation in lungs (Figure 5D, right) as previously reported (Ishikawa et al., 2009). In contrast, the same amount of Man-LAM induced neither lung swelling (Figure 5C) nor granuloma formation (Figure 5D, middle). These results indicate that Man-LAM does not induce strong pulmonary inflammation compared with other PAMPs such as TDM or LPS.

Man-LAM Stimulation Enhances APC Functions to Promote IL-17 Production In Vitro

We further evaluated the adjuvant activity of Man-LAM in vitro. To investigate the effect of Man-LAM on DC maturation, we examined the expression of costimulatory molecules on BMDCs after Man-LAM stimulation. Man-LAM stimulation upregulated the expression of CD40 and CD80 on WT BMDCs, which were comparable to those induced by LPS (Figure 6A). However, the induction of these costimulatory molecules was abolished in the absence of Dectin-2 and its subunit FcRγ (Figure 6A). Mincle was dispensable for the LAM-induced responses. We confirmed that the LPS-mediated responses were not altered in these mice. These results demonstrate that Man-LAM promotes DC maturation in a Dectin-2-dependent manner.

We next examined the function of antigen-presenting cells (APCs) upon Man-LAM stimulation. BMDCs were pulsed with the ovalbumin (OVA) antigen peptides and cocultured with T cells obtained from OVA-specific OT-II TCR transgenic mice in the presence or absence of Man-LAM. Because T cells do not express Dectin-2 (Ariizumi et al., 2000), this system enables us to evaluate the role of Man-LAM in APC functions toward T cell priming and activation. The antigen-specific secretion of IL-17 from CD4^{+} OT-II T cells was significantly augmented when the cells were cocultured with Man-LAM-treated APCs (Figure 6B). However, this enhancement was markedly attenuated when *Clec4n*$^{-/-}$ APCs were used. The antigen-induced T cell proliferation, as assessed by CFSE dilution, was observed regardless of Dectin-2 expression on DCs (Figure 6B, bottom). The concentration of IL-10 in coculture supernatant was increased depending on the antigen dose, suggesting the generation of IL-10-producing T cells in the presence of DCs stimulated through Man-LAM-Dectin-2 axis (Figure 6B).



Figure 6. LAM Induces Acquired Immune Responses through Dectin-2

(A) BMDCs obtained from WT, *Clec4n*$^{-/-}$, *Clec4e*$^{-/-}$, or *Fcer1g*$^{-/-}$ mice were left untreated or stimulated with plate-coated LAM or LPS for 48 hr. The surface expressions of CD40 and CD80 were analyzed using flow cytometry.

(B) BMDCs were pulsed with $OVA_{323-339}$ peptides and cocultured with CFSE-labeled $CD4^+$ OT-II T cells for 3 days in the presence or absence of plate-coated LAM. Cytokine concentrations were determined using ELISA. Cell proliferation was analyzed using flow cytometry for dilution of CFSE within the $CD4^+$ population. The data are presented as the means ± SD of triplicate and are representative of three separate experiments.

(C and D) WT (n = 10) and *Clec4n*$^{-/-}$ (n = 10) mice were immunized with MOG_{35-55} peptide in IFA containing LAM (500 μg) as described in Figure 1A. Mean clinical score (C) and disease incidence (D) at the indicated times were plotted.

(E) Lymph nodes were collected at 23 days after immunization for EAE and stimulated with MOG_{35-55} peptide for 4 days. Cytokine concentrations were determined using ELISA. The data are presented as the means ± SD.

See also Figure S5.

Man-LAM induced weak T cell proliferation in T cell-DC coculture even in the absence of antigen, which also required Dectin-2 on DCs (Figure 6B). This "antigen-independent proliferation" might be conferred by a large amount of IL-2 secretion through Dectin-2 on DCs (Figure 4C), because the addition of anti-IL-2 neutralizing mAb ablated this response (Figure S5A).

In contrast to the enhancement of IL-17 production, Man-LAM treatment had essentially no effect on the antigen-dependent IFN-γ production (Figure 6B). IL-4 was not detected at any time point in this experiment (data not shown). Collectively, these in vitro results suggest that Man-LAM stimulation enhances APC functions to promote IL-17 production in a Dectin-2-dependent manner.

Man-LAM Promotes Antigen-Specific Human T Cell Responses through Human Dectin-2

We then assessed whether Man-LAM influences human T cell responses as observed in murine T cells. Importantly, Man-LAM activated reporter cells expressing hDectin-2, and this activity was blocked in the presence of anti-hDectin-2 mAb (Figure S5B). The Man-LAM-induced cytokine production in human monocytes and monocyte-derived DCs was also significantly suppressed by anti-hDectin-2 mAb (Figures S5C and S5D). Peripheral blood mononuclear cells (PBMCs) from tuberculosis patients were stimulated with C10 peptide (VVRFQEAANKQKQEL) of CFP-10 (10 kDa culture filtrate antigen) from *M. tuberculosis*. Antigen peptides alone induced a substantial amount of IFN-γ production in PBMCs, whereas it was augmented upon Man-LAM stimulation in combination with antigen peptides. Man-LAM-induced augmentation of IFN-γ production was markedly compromised in the presence of anti-hDectin-2 mAb (Figure S5E). The Dectin-2-dependent enhancement of IFN-γ production was also observed in three other individuals (Figure S5F). These results indicate that Man-LAM-hDectin-2 interaction promotes the mycobacterial antigen-specific responses of T cells from tuberculosis patients, presumably through the activation of myeloid cells in PBMCs.



Figure 7. Immune Responses against Mycobacterial Infection in *Clec4n*$^{-/-}$ Mice

(A) Higher lung weights in *Clec4n*$^{-/-}$ mice. Lungs were isolated 23 days after infection of MAC. WT (n = 10) and *Clec4n*$^{-/-}$ (n = 10) mice were used.

(B) Histological analysis of the lung from uninfected- or MAC-infected WT or *Clec4n*$^{-/-}$ mice by HE staining. Scale bars represent 0.1 mm.

(C) Cytokine production in splenocytes after restimulation with sensitin or MACAg85 for 4 days. Splenocytes were obtained 23 days after infection of MAC and pooled from ten mice in each group. The data are presented as mean ± SD.

See also Figure S6.

Induction of EAE through Man-LAM Immunization via Dectin-2-FcRγ Axis

We next performed a murine model of T helper 17 (Th17) cell-mediated autoimmune disease, EAE, since Dectin-2 activation by Man-LAM induced IL-17 production in vitro (Figure 6B). Strikingly, *Clec4n*$^{-/-}$ mice were completely resistant to Man-LAM-induced EAE (Figures 6C and 6D), indicating that other Man-LAM receptors cannot compensate for the loss of Dectin-2 in vivo. Furthermore, ex vivo recall responses, as assessed by the production of IL-17, IFN-γ, and GM-CSF, of the lymph node cells collected from inguinal, lumbar, and axillary lymph nodes were completely abrogated in *Clec4n*$^{-/-}$ mice (Figure 6E). This indicates that Man-LAM cannot efficiently prime T cells in Dectin-2-deficient environment. Taken together, Dectin-2 is a receptor essential for the adjuvanticity of Man-LAM in vivo.

Role of Dectin-2 in Mycobacterial Infection

Finally, we examined the role of Dectin-2 in mycobacterial infection in vivo. WT and *Clec4n*$^{-/-}$ mice were infected intranasally with *M. avium* complex (MAC). Although the bacterial burden in the lungs was not significantly altered at 3 weeks after infection, the average number of colony forming units (CFU) per lungs was larger in *Clec4n*$^{-/-}$ mice than in WT mice (WT, 6.54 ± 6.47; *Clec4n*$^{-/-}$, 13.1 ± 8.32 [× 10^2]). We therefore characterized the lung pathology of infected mice. Lung swelling as assessed from lung mass was significantly greater in *Clec4n*$^{-/-}$ mice (Figure 7A). In addition, *Clec4n*$^{-/-}$ mice presented with increased histopathology in the lungs after infection (Figure 7B). Chemokine concentrations were elevated in the lungs of *Clec4n*$^{-/-}$ mice compared with WT mice 3 weeks after infection (Figure S6). These chemokines seemed to be induced by bacteria residing in the lungs, because the chemokine concentration in each individual mouse was correlated with the bacterial burden in the lungs (data not shown). The production of cytokines, such as TNF, IL-6, and IL-10, were not elevated in the lungs of WT and *Clec4n*$^{-/-}$ mice at day 23 after infection (data not shown). We also examined antigen-specific T cell responses in the infected mice. Splenic T cells from *Clec4n*$^{-/-}$ mice produced a significantly larger amount of IFN-γ upon recall stimulation by mycobacterial antigens, whereas IL-17 production was not altered (Figure 7C). Thus, Dectin-2 deficiency resulted in augmented lung pathology and acquired immunity presumably due to the inefficient elimination of mycobacteria. Collectively, these results suggest that Dectin-2 is involved in host defense against mycobacteria.

DISCUSSION

In this manuscript, we have demonstrated that Dectin-2 is a direct and functional receptor for mycobacterial Man-LAM.

Mincle, MCL, and Dectin-2 are located in the same gene cluster, and we found that all these CLRs recognize mycobacteria (Ishikawa et al., 2009; Miyake et al., 2013). The acquisition of different CLRs recognizing distinct mycobacterial components during evolution would enable the host to exert stable immune responses against this life-threatening bacteria.

Dectin-2 has been reported to recognize high-mannose structures of fungi (McGreal et al., 2006), such as α-1,2-mannan derived from *Candida albicans* (Robinson et al., 2009; Saijo et al., 2010) and mannoprotein from *Malassezia* fungus (Ishikawa et al., 2013). Glycan array analysis confirms that Dectin-2 preferentially binds to high-mannose structures, similar to DC-SIGN, SIGNR1, SIGNR3, and MMR (McGreal et al., 2006), all of which possess the mannose-binding EPN sequence within their carbohydrate recognition domains (CRDs) (Drickamer, 1992). Man-LAM possesses polysaccharide chains that terminates in a α-1,2-mannose cap (Mishra et al., 2011). It is highly likely that the α-1,2-linked mannose residues of Man-LAM are the direct determinant recognized by Dectin-2.

Man-LAM is densely distributed in the envelopes of mycobacteria with the specific configuration, and thereby their polar mannose caps are exposed on the bacterial surface with oligomeric valency. The multivalent α-1,2-mannose residue is not inconsistent with the characteristics of PAMPs recognized by Dectin-2 (Ishikawa et al., 2013; Saijo et al., 2010). To replicate this configuration in vitro, Man-LAM was used as plate-coated form to evaluate Dectin-2-mediated responses in this study. Previous studies show that soluble Man-LAM alone does not induce cytokine production in myeloid cells (Geijtenbeek et al., 2003; Gringhuis et al., 2009; Nigou et al., 2001) and we confirmed this with BMDCs (data not shown). These different outcomes depending on the stimuli might be attributed to the difference in the receptor engagement caused by the nature of the ligand—monovalent (soluble) versus multivalent (immobilized). It has been demonstrated that soluble Man-LAM influences myeloid cell function in the presence of other stimuli such as TLR ligands (Geijtenbeek et al., 2003; Gringhuis et al., 2007; Nigou et al., 2001). One possible explanation for these findings is that TLR-bound lipoprotein might provide a scaffold for soluble Man-LAM through hydrophilic interaction in aqueous media, which leads to ligand multimerization sufficient for the engagement of Dectin-2. Consistent with these ideas, multimerized Man-LAM in oil emulsion exhibited potent adjuvant activity in vivo. Collectively, Dectin-2 might discriminate multivalent PAMPs presented on "real" pathogens, presumably to prevent false recognition of their targets.

The α-1,2-linked mannose residues are also present in phosphatidyl-*myo*-inositol mannosides (PIMs). Because PIMs have been shown to be potentially associated with MMR and DC-SIGN (Torrelles et al., 2006), Dectin-2 might recognize PIMs. However, *M. abscessus*, which lacks Man-LAM but possesses PIMs, did not activate reporter cells expressing Dectin-2, implying that PIMs might not be a potent ligand for Dectin-2. Alternatively, Dectin-2 may not be able to access "short" PIMs within "tall" cell wall components, such as long-chain mycolic acids, glycolipids, lipoglycans, and polysaccharides (Mishra et al., 2011; Torrelles et al., 2006).

SIGNR1, SIGNR3, and MMR have been reported as murine receptors for Man-LAM (Koppel et al., 2004; Schlesinger et al., 1994; Tanne et al., 2009). Peritoneal macrophages from *Cd209b*$^{-/-}$ mice produce less, but detectable, IL-10 in response to Man-LAM (Wieland et al., 2007). However, gene ablation of SIGNR1 and anti-MMR blocking mAb did not influence the LAM-induced cytokine production in BMDCs. SIGNR3 is not expressed on BMDCs and forced expression of SIGNR3 did not rescue cytokine production in *Clec4n*$^{-/-}$ BMDCs. Thus, the characteristic cytokine production induced by Man-LAM seems to be determined by intrinsic signaling via Dectin-2 in DCs. Although Man-LAM-induced in vivo responses were also completely abolished in *Clec4n*$^{-/-}$ mice, it is possible that SIGNR3 plays a role in Man-LAM responses in particular cells, such as dermal DCs, that express SIGNR3 (Nagaoka et al., 2010). Alternatively, these Man-LAM-binding molecules might promote the binding of myeloid cells to Man-LAM-bearing bacteria (Tanne et al., 2009), thereby leading to the efficient phagocytosis of mycobacteria.

Our data demonstrate that Man-LAM is a sufficient component to trigger IL-10 production. However, we cannot exclude the possibility that Man-LAM is not necessarily required for IL-10 production induced by whole mycobacteria, although NTM strain *M. abscessus* lacking Man-LAM did not induce IL-10 production. The results from mutant *M. bovis* BCG, which lacks the mannose cap of LAM, suggest its redundant role in IL-10 production in LPS-primed human DCs (Appelmelk et al., 2008). It has been reported that mycobacteria may possess other possible unidentified Dectin-2 ligands, such as mannosylated proteins (Pitarque et al., 2005). These components might account, at least in part, for the IL-10 production induced by whole bacteria.

It has been reported that the IL-10 production during infection correlates with susceptibility to *M. tuberculosis*. Large amounts of IL-10 can be detected in the serum of active tuberculosis patients, particularly in response to hypervirulent strains of *M. tuberculosis* (O'Garra et al., 2013). In line with these observations, increased susceptibility to mycobacteria has been shown in mice that constitutively overexpressed IL-10 (Feng et al., 2002). In addition, secretion of another immune-regulatory cytokine transforming growth factor-β (TGF-β) was also slightly enhanced by Man-LAM through Dectin-2 (data not shown). However, the precise contribution of the mannose cap of LAM to the virulency of mycobacteria still remains controversial in vivo (Afonso-Barroso et al., 2012; Appelmelk et al., 2008).

On the other hand, it has been proposed that IL-10 might limit excessive damage to the host tissue (Redford et al., 2011). The mutant mice lacking CARD9, a downstream adaptor of FcRγ, exhibited severe lung pathology and enhanced lethality in response to *M. tuberculosis*, which is correlated with abolished secretion of IL-10 (Dorhoi et al., 2010). Although CARD9 also mediates signaling through Mincle, the effect of Mincle deficiency on the pathologies during mycobacterial infection was modest compared with those of *CARD9*$^{-/-}$ mice (Behler et al., 2012; Heitmann et al., 2013; Lee et al., 2012). Given the augmented lung inflammation in *Clec4n*$^{-/-}$ mice, the Dectin-2-FcRγ-CARD9 axis appears to be involved in the control of mycobacterial infection. Indeed, *Fcer1g*$^{-/-}$ mice showed increased immunopathology in the lungs during mycobacterial infection (Maglione et al., 2008).

How does Man-LAM efficiently promote Th17 cell responses in mice? A previous study demonstrates that Dectin-2 ligand is

capable of inducing the Th17 cell differentiation through the release of soluble factors (Saijo et al., 2010). Man-LAM stimulation also induced the production of IL-6, TNF, and TGF-β, all of which are Th17-cell-inducing cytokines. In addition, we observed that the transcription of IL-23p19 was upregulated in BMDCs upon Man-LAM in a Dectin-2-dependent fashion (data not shown), as previously reported in BMDCs stimulated with *C. albicans* (Robinson et al., 2009). A recent report has demonstrated that a NTM strain *M. avium* bearing Man-LAM could induce IL-23 production. This activity is lost in the lipophilic extract of the strain (Jönsson et al., 2012), supporting the idea that hydrophilic Man-LAM is involved in the promotion of Th17 cell differentiation.

In human PBMCs from tuberculosis patients, we found that Man-LAM enhanced IFN-γ production induced by mycobacterial antigen. The undetectable concentration of IL-17 secretion (data not shown) is consistent with previous observation (Yamashita et al., 2013), although the underlying mechanism is currently unknown. One possible explanation is that T cells in tuberculosis patients might have already skewed to a Th1 cell phenotype upon repetitive antigen exposure during infection.

In sharp contrast to Mincle ligand TDM, Dectin-2 ligand Man-LAM uniquely induces the production of IL-10 and IL-2, despite the fact that both CLRs share the same signaling subunit FcRγ. IL-2 production from DCs might contribute to the adjuvanticity by promoting T cell priming (Granucci et al., 2001). Previous studies have highlighted the role of Syk-CARD9 pathway in the production of IL-10 and IL-2 in DCs (LeibundGut-Landmann et al., 2007; Robinson et al., 2009; Saijo et al., 2010), because the TLR-MyD88 or TRIF pathway does not lead to secretion of these cytokines (LeibundGut-Landmann et al., 2007). However, the Syk-CARD9 pathway is not sufficient to induce these cytokines, because the Mincle ligand TDM did not allow the production of either IL-10 or IL-2. It remains unclear how distinct CLRs lead to different cellular responses through a common signaling subunit. We previously reported that the quantity and duration of FcRγ signals can determine the quality of cellular responses (Yamasaki et al., 2004). It is intriguing to hypothesize that the kinetics, affinity, or valency of receptor engagement potentially generates distinct signaling through FcRγ.

In addition to the functions of Man-LAM described above, Man-LAM is known to have pleiotropic functions during mycobacterial infection. Mycobacteria limit phagosome-lysosome fusion to survive in macrophages, which allow mycobacteria to establish latent and persistent infection (Pieters, 2008). Man-LAM is one of the candidate involved in this process (Fratti et al., 2003; Vergne et al., 2004), although more detailed studies are needed to determine whether Dectin-2-mediated signaling affects phagosome-lysosome fusion. A recent study has demonstrated that Man-LAM treatment inhibits T cell migration from the draining lymph nodes (Richmond et al., 2012). This effect seems to occur independently of Dectin-2, as its expression was not detected in any subsets of T cells (Ariizumi et al., 2000).

In the present study, we have shown that Dectin-2 recognizes Man-LAM to mediate its adjuvanticity. In addition, the simultaneous induction of both immunostimulatory and inhibitory responses by Man-LAM-Dectin-2 axis might be beneficial for host organisms to maintain balanced immune responses. During EAE development, skin inflammation is observed at the injection site when TDM was used as an adjuvant (Miyake et al., 2013). However, no such inflammation was observed in the skin of Man-LAM-injected mice (data not shown), implying that the anti-inflammatory cytokines induced by Man-LAM might control excessive inflammation at the injection site. The limited inflammatory responses induced by Man-LAM could thus be beneficial as an adjuvant for therapeutic vaccines for infectious diseases and cancer. It is therefore proposed that Man-LAM analogs might represent unique hydrophilic "regulatory" adjuvants that promote the development of acquired immunity, with minimal detrimental inflammation.

EXPERIMENTAL PROCEDURES

Lipids Extract

M. bovis BCG was fractionated by distilled water with repeated washing five times. After centrifugation, the soluble fraction was collected. The insoluble fraction was further delipidated with C:M (2:1, vol/vol). Each fraction was resuspended in a volume of isopropanol at equivalent amount of 0.1 mg as the original *M. bovis* BCG weight.

Cells

2B4-NFAT-GFP reporter cells expressing FcRγ alone, Mincle, Dectin-2, and Dectin-2^{QPD} were prepared as previously described (Yamasaki et al., 2009). BMDCs were prepared as previously described (Miyake et al., 2013).

In Vitro Stimulation

Mycobacterial lipid extracts, LAM in aqueous solution (1 mg/ml), TDM dissolved in C:M at 1 mg/ml, and *Candida albicans* cell wall mannan (5 mg/ml) were diluted in isopropanol and added to 96-well plates at 20 μl/well, followed by evaporation of the solvents as previously described (Ishikawa et al., 2009). Reporter cells were stimulated for 24 hr and the activation of NFAT-GFP was monitored using flow cytometry. BMDCs were stimulated for 2 days, then the culture supernatants were collected. The concentrations of each cytokine were determined by ELISA. Activation was determined using surface staining of the costimulatory molecules CD40 and CD80 by flow cytometry.

OVA-Specific CD4⁺ T Cell Responses

BMDCs were generated from WT and *Clec4n*$^{-/-}$ mice as described above. BMDCs were left untreated or stimulated with indicated amount of plate-coated LAM in the presence of $OVA_{323-339}$ peptides (ABGENT). CD4⁺ T cells from OT-II Tg mice were purified with anti-CD4-conjugated magnetic beads (MACS, Miltenyi) and then labeled with CFSE (DOJINDO) and cocultured with OVA-pulsed DCs in 96-well plates. On day 3, the supernatants were harvested and determined the concentration of IFN-γ, IL-17, and IL-10 using ELISA. CFSE-labeled T cells were analyzed for dilution of CFSE within the CD4⁺ T cell population using flow cytometry.

Experimental Autoimmune Encephalomyelitis

Mice were immunized via subcutaneous administration of 200 μg of MOG_{35-55} peptide (Invitrogen) emulsified in IFA (Difco) containing 500 μg of LAM on day 0. The mice received three daily intraperitoneal (i.p.) administrations of 500 ng of pertussis toxin (PT) (List Biological Laboratories) starting on day 1. The disease severity was scored as previously described (Miyake et al., 2013). For the in vitro restimulation analysis, cells were collected from the axillary, inguinal, and lumbar (paraaortic) lymph nodes on day 23. Lymphocytes (5×10^5 cells/well) were stimulated with MOG_{35-55} peptides at the indicated concentrations for 4 days. The concentrations of IL-17, IFN-γ, and GM-SCF in culture supernatants were determined by ELISA. All animal protocols were approved by the committee of Ethics on Animal Experiment, Faculty of Medical Sciences, Kyushu University, Chiba University, or Tokyo University of Pharmacy and Life Sciences.

Mycobacterial Infection

For in vitro infection, BMDCs were infected with 1 to 10×10^9 CFU of *M. bovis* BCG. After 48 hr, the culture supernatants were collected and cytokine

concentration was determined by ELISA. For in vivo infection, WT mice and *Clec4n*$^{-/-}$ mice were anesthetized with isoflurane, and each mouse was subsequently infected intranasally with 2.5×10^6 CFU *M. avium* complex (MAC) per mouse. At 3 weeks after infection, the lungs were isolated and homogenized with a Physcotron handy microhomogenizer (Microtec). Serial dilutions of the homogenates were subjected to the determination of CFU on 7H11 agar plates supplemented with OADC and penicillin (100 U/ml). The homogenates were also subjected to the determination of chemokines with a Cytometric Bead Array System (BD Biosciences). Lungs from other infected mice were fixed with 10% formaldehyde for hematoxylin-eosin staining. Single-cell suspensions of splenocytes (5×10^5 cells) were stimulated with *M. avium* sensitin PPD (5 μg/ml) or MAC Ag85A (10 μg/ml) for 4 days, and the concentrations of cytokines and chemokines in culture supernatants were determined by ELISA. Four patients of National Tokyo Hospital in Tokyo, Japan, were enrolled in this study after giving informed consent. The research protocol was approved by the Institutional Review Board of National Tokyo Hospital and by the ethical committee of the National Institute of Infectious Diseases for medical research using human subjects.

SUPPLEMENTAL INFORMATION

Supplemental Information includes six figures and Supplemental Experimental Procedures and can be found with this article online at http://dx.doi.org/10.1016/j.immuni.2014.08.005.

AUTHOR CONTRIBUTIONS

A.Y., S.S., and S.Y. designed the research; A.Y., S.S., Y.H., Y.M., E.I., M.S., and M.Y. did the experiments; H.I., M.T., and K.A. provided the materials; and A.Y., S.S., M.O., and S.Y. wrote the manuscript.

ACKNOWLEDGMENTS

We thank I. Yano, Y. Morita, K. Kawakami, D. Mori, and K. Toyonaga for discussion; S. Akira and T. Saito for providing mice; K. Machida, K. Wakamatsu, and Y. Koreeda for providing NTM strains; T. Kamichi for technical support; Y. Sanui for secretarial assistance; and Laboratory for Technical Support, Medical Institute of Bioregulation, Kyushu University for support. This work was partly performed in the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University and Medical Mycology Research Center, Chiba University. This work was supported by Funding Program for Next Generation World-Leading Researcher (NEXT Program) and Coordination, Support and Training Program for Translational Research and Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology.

Received: December 25, 2013
Accepted: August 7, 2014
Published: August 28, 2014

REFERENCES

Afonso-Barroso, A., Clark, S.O., Williams, A., Rosa, G.T., Nóbrega, C., Silva-Gomes, S., Vale-Costa, S., Ummels, R., Stoker, N., Movahedzadeh, F., et al. (2012). Lipoarabinomannan mannose caps do not affect mycobacterial virulence or the induction of protective immunity in experimental animal models of infection and have minimal impact on in vitro inflammatory responses. Cell. Microbiol. *15*, 660–674.

Appelmelk, B.J., den Dunnen, J., Driessen, N.N., Ummels, R., Pak, M., Nigou, J., Larrouy-Maumus, G., Gurcha, S.S., Movahedzadeh, F., Geurtsen, J., et al. (2008). The mannose cap of mycobacterial lipoarabinomannan does not dominate the *Mycobacterium*-host interaction. Cell. Microbiol. *10*, 930–944.

Ariizumi, K., Shen, G.L., Shikano, S., Ritter, R., 3rd, Zukas, P., Edelbaum, D., Morita, A., and Takashima, A. (2000). Cloning of a second dendritic cell-associated C-type lectin (dectin-2) and its alternatively spliced isoforms. J. Biol. Chem. *275*, 11957–11963.

Behler, F., Steinwede, K., Balboa, L., Ueberberg, B., Maus, R., Kirchhof, G., Yamasaki, S., Welte, T., and Maus, U.A. (2012). Role of Mincle in alveolar macrophage-dependent innate immunity against mycobacterial infections in mice. J. Immunol. *189*, 3121–3129.

Belanger, A.E., Besra, G.S., Ford, M.E., Mikusová, K., Belisle, J.T., Brennan, P.J., and Inamine, J.M. (1996). The *embAB* genes of *Mycobacterium avium* encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc. Natl. Acad. Sci. USA *93*, 11919–11924.

Briken, V., Porcelli, S.A., Besra, G.S., and Kremer, L. (2004). Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol. Microbiol. *53*, 391–403.

Chan, E.D., Morris, K.R., Belisle, J.T., Hill, P., Remigio, L.K., Brennan, P.J., and Riches, D.W. (2001). Induction of inducible nitric oxide synthase-NO* by lipoarabinomannan of *Mycobacterium tuberculosis* is mediated by MEK1-ERK, MKK7-JNK, and NF-kappaB signaling pathways. Infect. Immun. *69*, 2001–2010.

Dorhoi, A., Desel, C., Yeremeev, V., Pradl, L., Brinkmann, V., Mollenkopf, H.J., Hanke, K., Gross, O., Ruland, J., and Kaufmann, S.H. (2010). The adaptor molecule CARD9 is essential for tuberculosis control. J. Exp. Med. *207*, 777–792.

Drickamer, K. (1992). Engineering galactose-binding activity into a C-type mannose-binding protein. Nature *360*, 183–186.

Feng, C.G., Kullberg, M.C., Jankovic, D., Cheever, A.W., Caspar, P., Coffman, R.L., and Sher, A. (2002). Transgenic mice expressing human interleukin-10 in the antigen-presenting cell compartment show increased susceptibility to infection with *Mycobacterium avium* associated with decreased macrophage effector function and apoptosis. Infect. Immun. *70*, 6672–6679.

Fratti, R.A., Chua, J., Vergne, I., and Deretic, V. (2003). *Mycobacterium tuberculosis* glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc. Natl. Acad. Sci. USA *100*, 5437–5442.

Geijtenbeek, T.B., Van Vliet, S.J., Koppel, E.A., Sanchez-Hernandez, M., Vandenbroucke-Grauls, C.M., Appelmelk, B., and Van Kooyk, Y. (2003). Mycobacteria target DC-SIGN to suppress dendritic cell function. J. Exp. Med. *197*, 7–17.

Granucci, F., Vizzardelli, C., Pavelka, N., Feau, S., Persico, M., Virzi, E., Rescigno, M., Moro, G., and Ricciardi-Castagnoli, P. (2001). Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat. Immunol. *2*, 882–888.

Gringhuis, S.I., den Dunnen, J., Litjens, M., van Het Hof, B., van Kooyk, Y., and Geijtenbeek, T.B. (2007). C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity *26*, 605–616.

Gringhuis, S.I., den Dunnen, J., Litjens, M., van der Vlist, M., and Geijtenbeek, T.B. (2009). Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to *Mycobacterium tuberculosis*, HIV-1 and *Helicobacter pylori*. Nat. Immunol. *10*, 1081–1088.

Heitmann, L., Schoenen, H., Ehlers, S., Lang, R., and Hölscher, C. (2013). Mincle is not essential for controlling *Mycobacterium tuberculosis* infection. Immunobiology *218*, 506–516.

Ishikawa, E., Ishikawa, T., Morita, Y.S., Toyonaga, K., Yamada, H., Takeuchi, O., Kinoshita, T., Akira, S., Yoshikai, Y., and Yamasaki, S. (2009). Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J. Exp. Med. *206*, 2879–2888.

Ishikawa, T., Itoh, F., Yoshida, S., Saijo, S., Matsuzawa, T., Gonoi, T., Saito, T., Okawa, Y., Shibata, N., Miyamoto, T., and Yamasaki, S. (2013). Identification of distinct ligands for the C-type lectin receptors Mincle and Dectin-2 in the pathogenic fungus *Malassezia*. Cell Host Microbe *13*, 477–488.

Jönsson, B., Ridell, M., and Wold, A.E. (2012). Non-tuberculous mycobacteria and their surface lipids efficiently induced IL-17 production in human T cells. Microbes Infect. *14*, 1186–1195.

Józefowski, S., Sobota, A., Pawłowski, A., and Kwiatkowska, K. (2011). *Mycobacterium tuberculosis* lipoarabinomannan enhances LPS-induced

TNF-α production and inhibits NO secretion by engaging scavenger receptors. Microb. Pathog. *50*, 350–359.

Koppel, E.A., Ludwig, I.S., Hernandez, M.S., Lowary, T.L., Gadikota, R.R., Tuzikov, A.B., Vandenbroucke-Grauls, C.M., van Kooyk, Y., Appelmelk, B.J., and Geijtenbeek, T.B. (2004). Identification of the mycobacterial carbohydrate structure that binds the C-type lectins DC-SIGN, L-SIGN and SIGNR1. Immunobiology *209*, 117–127.

Lee, W.B., Kang, J.S., Yan, J.J., Lee, M.S., Jeon, B.Y., Cho, S.N., and Kim, Y.J. (2012). Neutrophils promote mycobacterial trehalose dimycolate-induced lung inflammation via the Mincle pathway. PLoS Pathog. *8*, e1002614.

LeibundGut-Landmann, S., Gross, O., Robinson, M.J., Osorio, F., Slack, E.C., Tsoni, S.V., Schweighoffer, E., Tybulewicz, V., Brown, G.D., Ruland, J., and Reis e Sousa, C. (2007). Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat. Immunol. *8*, 630–638.

Leopold, K., and Fischer, W. (1993). Molecular analysis of the lipoglycans of *Mycobacterium tuberculosis*. Anal. Biochem. *208*, 57–64.

Maglione, P.J., Xu, J., Casadevall, A., and Chan, J. (2008). Fc γ receptors regulate immune activation and susceptibility during *Mycobacterium tuberculosis* infection. J. Immunol. *180*, 3329–3338.

Mazurek, J., Ignatowicz, L., Kallenius, G., Svenson, S.B., Pawlowski, A., and Hamasur, B. (2012). Divergent effects of mycobacterial cell wall glycolipids on maturation and function of human monocyte-derived dendritic cells. PLoS ONE *7*, e42515.

McGreal, E.P., Rosas, M., Brown, G.D., Zamze, S., Wong, S.Y., Gordon, S., Martinez-Pomares, L., and Taylor, P.R. (2006). The carbohydrate-recognition domain of Dectin-2 is a C-type lectin with specificity for high mannose. Glycobiology *16*, 422–430.

Mishra, A.K., Driessen, N.N., Appelmelk, B.J., and Besra, G.S. (2011). Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in *Mycobacterium tuberculosis* physiology and host-pathogen interaction. FEMS Microbiol. Rev. *35*, 1126–1157.

Miyake, Y., Toyonaga, K., Mori, D., Kakuta, S., Hoshino, Y., Oyamada, A., Yamada, H., Ono, K.I., Suyama, M., Iwakura, Y., et al. (2013). C-type lectin MCL is an FcRγ-coupled receptor that mediates the adjuvanticity of mycobacterial cord factor. Immunity *38*, 1050–1062.

Nagaoka, K., Takahara, K., Minamino, K., Takeda, T., Yoshida, Y., and Inaba, K. (2010). Expression of C-type lectin, SIGNR3, on subsets of dendritic cells, macrophages, and monocytes. J. Leukoc. Biol. *88*, 913–924.

Nigou, J., Zelle-Rieser, C., Gilleron, M., Thurnher, M., and Puzo, G. (2001). Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor. J. Immunol. *166*, 7477–7485.

O'Garra, A., Redford, P.S., McNab, F.W., Bloom, C.I., Wilkinson, R.J., and Berry, M.P. (2013). The immune response in tuberculosis. Annu. Rev. Immunol. *31*, 475–527.

Pieters, J. (2008). *Mycobacterium tuberculosis* and the macrophage: maintaining a balance. Cell Host Microbe *3*, 399–407.

Pitarque, S., Herrmann, J.L., Duteyrat, J.L., Jackson, M., Stewart, G.R., Lecointe, F., Payre, B., Schwartz, O., Young, D.B., Marchal, G., et al. (2005). Deciphering the molecular bases of *Mycobacterium tuberculosis* binding to the lectin DC-SIGN reveals an underestimated complexity. Biochem. J. *392*, 615–624.

Redford, P.S., Murray, P.J., and O'Garra, A. (2011). The role of IL-10 in immune regulation during *M. tuberculosis* infection. Mucosal Immunol. *4*, 261–270.

Richmond, J.M., Lee, J., Green, D.S., Kornfeld, H., and Cruikshank, W.W. (2012). Mannose-capped lipoarabinomannan from *Mycobacterium tuberculosis* preferentially inhibits sphingosine-1-phosphate-induced migration of Th1 cells. J. Immunol. *189*, 5886–5895.

Robinson, M.J., Osorio, F., Rosas, M., Freitas, R.P., Schweighoffer, E., Gross, O., Verbeek, J.S., Ruland, J., Tybulewicz, V., Brown, G.D., et al. (2009). Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. J. Exp. Med. *206*, 2037–2051.

Saijo, S., Ikeda, S., Yamabe, K., Kakuta, S., Ishigame, H., Akitsu, A., Fujikado, N., Kusaka, T., Kubo, S., Chung, S.H., et al. (2010). Dectin-2 recognition of α-mannans and induction of Th17 cell differentiation is essential for host defense against *Candida albicans*. Immunity *32*, 681–691.

Sato, K., Yang, X.L., Yudate, T., Chung, J.S., Wu, J., Luby-Phelps, K., Kimberly, R.P., Underhill, D., Cruz, P.D., Jr., and Ariizumi, K. (2006). Dectin-2 is a pattern recognition receptor for fungi that couples with the Fc receptor γ chain to induce innate immune responses. J. Biol. Chem. *281*, 38854–38866.

Schlesinger, L.S., Hull, S.R., and Kaufman, T.M. (1994). Binding of the terminal mannosyl units of lipoarabinomannan from a virulent strain of *Mycobacterium tuberculosis* to human macrophages. J. Immunol. *152*, 4070–4079.

Tailleux, L., Schwartz, O., Herrmann, J.L., Pivert, E., Jackson, M., Amara, A., Legres, L., Dreher, D., Nicod, L.P., Gluckman, J.C., et al. (2003). DC-SIGN is the major *Mycobacterium tuberculosis* receptor on human dendritic cells. J. Exp. Med. *197*, 121–127.

Tanne, A., Ma, B., Boudou, F., Tailleux, L., Botella, H., Badell, E., Levillain, F., Taylor, M.E., Drickamer, K., Nigou, J., et al. (2009). A murine DC-SIGN homologue contributes to early host defense against *Mycobacterium tuberculosis*. J. Exp. Med. *206*, 2205–2220.

Torrelles, J.B., Azad, A.K., and Schlesinger, L.S. (2006). Fine discrimination in the recognition of individual species of phosphatidyl-myo-inositol mannosides from *Mycobacterium tuberculosis* by C-type lectin pattern recognition receptors. J. Immunol. *177*, 1805–1816.

Vergne, I., Chua, J., Singh, S.B., and Deretic, V. (2004). Cell biology of *mycobacterium tuberculosis* phagosome. Annu. Rev. Cell Dev. Biol. *20*, 367–394.

Wieland, C.W., Koppel, E.A., den Dunnen, J., Florquin, S., McKenzie, A.N., van Kooyk, Y., van der Poll, T., and Geijtenbeek, T.B. (2007). Mice lacking SIGNR1 have stronger T helper 1 responses to *Mycobacterium tuberculosis*. Microbes Infect. *9*, 134–141.

Yamasaki, S., Ishikawa, E., Kohno, M., and Saito, T. (2004). The quantity and duration of FcRgamma signals determine mast cell degranulation and survival. Blood *103*, 3093–3101.

Yamasaki, S., Matsumoto, M., Takeuchi, O., Matsuzawa, T., Ishikawa, E., Sakuma, M., Tateno, H., Uno, J., Hirabayashi, J., Mikami, Y., et al. (2009). C-type lectin Mincle is an activating receptor for pathogenic fungus, *Malassezia*. Proc. Natl. Acad. Sci. USA *106*, 1897–1902.

Yamashita, Y., Hoshino, Y., Oka, M., Matsumoto, S., Ariga, H., Nagai, H., Makino, M., Ariyoshi, K., and Tsunetsugu-Yokota, Y. (2013). Multicolor flow cytometric analyses of $CD4^+$ T cell responses to *Mycobacterium tuberculosis*-related latent antigens. Jpn. J. Infect. Dis. *66*, 207–215.

Zhu, L.L., Zhao, X.Q., Jiang, C., You, Y., Chen, X.P., Jiang, Y.Y., Jia, X.M., and Lin, X. (2013). C-type lectin receptors Dectin-3 and Dectin-2 form a heterodimeric pattern-recognition receptor for host defense against fungal infection. Immunity *39*, 324–334.

感染

次世代ワクチンの方向性

あおし・たいき
1999年浜松医科大学医学部卒業. 浜松医科大学医学部微生物学助手，ワシントン大学（セントルイス）医学部免疫学研究員，大阪大学微生物病研究所分子原虫学分野特任助教を経て，2010年より医薬基盤研究所アジュバント開発プロジェクト主任研究員.

青枝　大貴[1, 2)*]，石井　健[1, 2)]

Summary

ワクチンは免疫のしくみを利用した医療技術の１つであり，天然痘やポリオなどの感染症制御に大きな役割を果たすだけでなく，がん，アルツハイマー，アレルギーなどの疾患に対しても有効な手立てとなることも期待されている．近年の微生物学，免疫学の発展によってこれまで経験的に理解され用いられていたワクチンという技術が分子や細胞の言葉で再構築できるようになりつつあり，個々の接種者の利益を優先したワクチンの個別化が可能となりつつある．本稿では現在のワクチン全般について，抗原，アジュバント，デリバリーシステム，自然免疫，獲得免疫などの視点から概説し，次世代のワクチンについて考察する．

Key words：ワクチン，アジュバント，自然免疫，獲得免疫，抗原，デリバリーシステム，抗原提示細胞

Ⅰ．ワクチンのはじまり

現在のワクチンへとつながる疫病（天然痘）を防ぐ試みは1,000年以上も前に中国やインドで行われていたとされる人痘接種（Variolation）の記録にはじまる．その当時から天然痘が流行すると感染者の約30％が死亡したとされているが，人痘接種では，それが天然痘流行の引き金になることもあったものの，一方で成功すればその死亡率は１％程度で，実際に天然痘流行時に感染するよりもはるかに低い死亡率だったとされている．その後18世紀の終わりにEdward Jennerによって人痘ではなく牛痘を用いると接種そのものに由来する感染死を起こすことなく天然痘に対する抵抗性（免疫）を賦与できること（種痘法）が発見され，このような方法は牛を意味するラテン語vaccaにちなんでvaccinationと名付けられ，長い時間をかけて世界中に広がっていった．第二次世界大戦を経た1945年時点でも天然痘は未だ日本を含む世界の多くの国々で蔓延していたが，1958年に世界保健機関（WHO）総会で「世界天然痘根絶計画」が可決され，これによって種痘法による天然痘の根絶は世界各地で急速に進展した．1977年のソマリアでの天然痘患者が最後の天然痘自然発生例となり，1980年にはWHOによる根絶宣言が行われた．現在，感染症を予防する目的で用いられる医薬品を総称してワクチンと呼ぶが，天然痘撲滅はまさにワクチンの金字塔であり，ワクチン（特に弱毒生ワクチン）の圧倒的な効果を象徴する事例の１つとなっている．

天然痘
天然痘ウイルスによる感染症で，高熱を伴う激しい全身症状とヘソのある水疱性発疹を特徴とし，治癒した場合でも醜い瘢痕を残す．感染力，致死率が高く，たびたび大きな流行を起こし古くから人類に甚大な被害を及ぼした．日本では1946年には天然痘で約3,000人が死亡していたが，ワクチン接種などにより沈静化し1956年以降には国内での発生はない．

Ⅱ．現在のワクチンとその課題

ジェンナー以降，微生物学および免疫学の発展によって感染症に対する免疫のしくみが徐々に明らかとなり，日本および世界の多くの国々では政策としてワクチンによる予防接種が行われている．現在日本で用いられているワクチンを表１に示す．日本の予防接種政策と海外との格差は「ワクチンギャップ」と呼ばれ議論の対象となっていたが，2012年の経口ポリオワクチン（OPV）から不活化ポリオワクチン（IPVおよびDPT-IPV）への切り替え，2013年からインフルエンザ菌ｂ型（Hib），肺炎球菌（PCV7，現在はPCV13），ヒトパピローマウイルス（HPV）に対するワクチンが定期接種化され，さらに水

1）独立行政法人医薬基盤研究所
アジュバント開発プロジェクト
〒567-0085
大阪府茨木市彩都あさぎ７－６－８
2）大阪大学免疫学フロンティア研究センターワクチン学
E-mail
t-aoshi@nibio.go.jp（青枝），
kenishii@nibio.go.jp（石井）

表1 現行ワクチンの種類とその特徴

	生ワクチン	不活化ワクチン		
		全粒子ワクチン	サブユニット，コンポーネント，リコンビナントワクチン	トキソイド（不活化外毒素）
特徴	毒性や病原性を弱めた微生物（クチ細菌やウイルス）をそのままワクチンとして用いる.	ホルマリンなどの化学処理で病原微生物をそのまま殺した（不活化した）もの.	病原体を不活化した後，破砕し，免疫に有用な成分（抗原）のみを高度に濃縮・精製したもの. 酵母やバキュロウイルスで発現させたリコンビナント蛋白質でウイルス様粒子を形成することもある.	病原体の産生する外毒素のみを精製し，ホルマリンなどで不活化したもの.
誘導される主な免疫反応	B細胞（抗体） CD4T細胞（Th1） CD8T細胞（CTL）	B細胞（抗体） CD4T細胞（Th1）	B細胞（抗体） CD4T細胞（Th2）	B細胞（抗体）
主なワクチン［外来性アジュバントは添加されていない］	BCG ポリオ（OPV） 麻疹風疹混合（MR） 麻疹 風疹 流行性耳下腺炎 水痘 ロタウイルス（1価，5価） 黄熱	A型肝炎 日本脳炎 狂犬病 不活化ポリオ（IPV）	インフルエンザHA 肺炎球菌（23価多糖体） インフルエンザ菌b型（Hib）	なし
主なワクチン［外来性アジュバント*, **が添加されている］	なし	プレパンデミックインフルエンザワクチン（A/H5N1）*	B型肝炎* 肺炎球菌（13価結合型）** ヒトパピローマウイルス2価［AS04］ ヒトパピローマウイルス4価［水酸化リン酸アルミニウム］	DPT* DPT-IPV* DT** 破傷風トキソイド* 成人用ジフテリアトキソイド**
ブタ由来新型インフルエンザ流行時の特例承認ワクチン（2010年1月）［MF59，AS03共にスクワレンを主体とするoil-in-water emulsion］			H1N1インフルエンザワクチン（CELTURA®；ノバルティス）［MF59］ H1N1インフルエンザワクチン（アレパンリックス®；GSK）［AS03］	

*水酸化アルミニウム
**リン酸アルミニウム

痘ワクチンと成人用肺炎球菌ワクチン（23価多糖体）も2014年10月に定期接種化される予定となっており，接種可能なワクチンの種類および費用面でのワクチンギャップはほぼ解消に向かっている．また，比較的近年になって開発されたH1N1新型インフルエンザワクチン（日本は特例承認）やHPVワクチンには免疫効果を高めるためにAS04，MF59，AS03といった新しいアジュバント（表5参照）が使用されている特徴がある．しかしながら，後に詳しく述べるが，AS04が使用されているHPVワクチン接種後にみられる長期体調不良例の報告[1]や，主に北欧諸国で報告が相次いだAS03が添加されたH1N1新型インフルエンザワクチン（日本は特例承認）接種後の明らかなナルコレプシー発症の増加[2,3]など，新しいアジュバントの使用に対して冷静にかつ科学的に検討すべき課題も指摘されている．さらに歴史的には感染症による疾病を克服するためにワクチンは発展してきたが，近年では感染症のみならず，がん，アレルギー，アルツハイマー，高血圧，自己免疫疾患など宿主の免疫反応が関与する多くの疾患に対して，宿主の免疫応答を介して作用するワクチンという手法が有効な手立てとなると考えられ[4,5]，実際にこれらの疾患を標的としたワクチン開発が進められている（表2.1，2.2）．また，まだ有効なワクチンが開発されていない多くの疾患が存在し，それらに対するワクチンの開発も望まれている[6]（表2.1，2.2）．日本国内では平成26年に策定された予防接種基本計画で表2.2にあげた6ワクチンが開発優先度の高いワクチンとされている．

表2.1　現在有効なワクチンがなく開発が望まれる疾患対象

ウイルス性疾患
サイトメガロウイルス
デング熱
Epstein-Barrウイルス
C型肝炎
単純ヘルペスウイルス
HIV
インフルエンザ(ユニバーサル)
RSV
ライノウイルス

細菌性疾患
カンピロバクター
クラミジア
ヘリコバクターピロリ
赤痢
連鎖球菌(A群，B群)
結核
尿路感染症

寄生虫疾患
リーシュマニア
マラリア
住血吸虫症

その他
アレルギー
自己免疫疾患
がん
アルツハイマー型認知症
高血圧

文献6より作成.

表2.2　開発優先度の高いワクチン(日本)

麻しん・風しん混合(MR)ワクチンを含む混合ワクチン
百日せき・ジフテリア・破傷風・不活化ポリオ混合(DPT-IPV)ワクチンを含む混合ワクチン
経鼻投与ワクチンなどの改良されたインフルエンザワクチン
ノロウイルスワクチン
RSウイルスワクチン
帯状疱疹ワクチン

予防接種基本計画　厚生労働省告示第121号(平成26年3月28日告示，平成26年4月1日適用)より作成.

表3　ワクチン療法と薬物治療の比較

	ワクチン	薬
構成	抗原(＋アジュバント)	低分子化合物，抗体医薬など
標的	抗原提示細胞(樹状細胞)	生体分子(ポリメラーゼ，レセプター，サイトカインなど)
エフェクター	抗体，T細胞	薬剤自身
作用機序	免疫反応誘導(能動的)	機能阻害または促進(受動的)
宿主免疫応答の誘導	望ましい(ワクチン効果)	望ましくない(薬剤アレルギーなど)
効果の持続	長期間(免疫記憶)	短期間
重篤な副作用(稀)	アナフィラキシー，ギランバレー症候群，急性散在性脳脊髄炎，ナルコレプシーなど	スティーブンス・ジョンソン症候群，薬物性肝障害など

Ⅲ．ワクチンと薬物治療との違い

ワクチンと一般的な薬物治療を比較すると，「ワクチン」では宿主の免疫反応を誘導することによってその効果をあらわす点がいわゆる「薬」とは大きく異なっているといえる（表3）．薬はある特定の分子の機能を促進あるいは阻害することでその薬物が存在している時にのみその効果を発揮するが，ワクチンは接種された抗原に対して一連の免疫カスケードを惹起するため，投与された抗原やアジュバントが存在しなくなっても，免疫記憶として残り，宿主に長期間影響を与えうる．一般的に薬に対する薬剤アレルギーなどの免疫反応は望ましくなく，重篤な場合は，スティーブンス・ジョンソン症候群や薬剤性肝障害によって死亡することもあるため，宿主の免疫機構から認識されないことが薬剤開発の1つの目標である．反対にワクチンにおいては，宿主の病原体に対する免疫応答を実際の感染によらず人工的に惹起して感染防御免疫を付与することが目的であり，免

表4 次世代ワクチンの特徴

	病原性	抗原	アジュバント	デリバリーシステム	ワクチン効果	理論上の安全性
弱毒生ワクチン	△ 非常に弱い	○ 全部	○ 内在性，天然	○ 感染，増殖	非常に高い	低い
全粒子，全菌体ワクチン（不活化）	×	○ 全部	○ 内在性，天然	△	高い	やや低い
コンポーネントワクチン（不活化，精製）	×	○ 一部	×	×	弱い	高い
次世代ワクチン（all-defined）	×	○ 合成ペプチドなど	○ 外来性，合成	○ 再構成 デザイン	確実な効果（高い予測可能性）	非常に高い（高い予測可能性）

疫反応を能動的に誘導することがワクチンの役割である．その際にワクチンに含まれる添加物に対する免疫応答の惹起，自己抗原に対しての免疫寛容機構の破綻などがおこると，アナフィラキシーショックやギランバレー症候群などの重篤な副作用が表出することになる（表3）．しかしながら，ウイルスや細菌による自然感染後にも同様の自己免疫機序によるギランバレー症候群などの病態はみられ，ワクチンによる自己免疫反応は多くの場合は自然感染によるものに比べて低頻度であると考えられている．これらの知見は，ワクチンの安全性を考える際に非常に重要であるが，逆に病原体に対する適切な免疫応答が誘導できれば，天然痘やポリオなどの事例のように，非常に効率的で効果的な医療技術であることも示している．

Ⅳ．各ワクチンタイプの利点と弱点

現在使用されているワクチンは弱毒生ワクチンと不活化ワクチンの2つに大別され，不活化ワクチンはさらにワクチンに含まれる病原体由来成分によって全粒子/全菌体ワクチン，コンポーネントワクチン，トキソイドに分けられる（表1，表4参照）．

弱毒生ワクチンは病原微生物を実験的な環境で繰り返し継代培養するとヒトに対する病原性が次第に弱くなるというパスツールの発見を基に樹立された弱毒ワクチン株を，生きたままヒトに接種する方法である．現在一般的に使用されているワクチンの約半数はこの弱毒生ワクチンである（表1参照）．微生物学の発展によって現在では多くの細菌やウイルスの病原性因子が同定されているが，今もって弱毒生ワクチンの開発は経験的な方法による部分が大きく，一度開発に成功すれば天然痘やポリオの事例にみるように非常に強力であるが，もともと野生型の微生物に由来することから，ワクチン接種に伴って感染に類似した症状や発熱などがみられることもあり，それらの安全性は実際での臨床使用による実証による部分が大きい．その意味で現在用いられている弱毒生ワクチンはいずれも長年にわたる臨床使用そのものによって安全性が実証されているともいえる．

全粒子/全菌体ワクチンは，病原微生物をホルマリンなどで化学的に死滅させた（不活化）病原体をそのまま全体としてワクチンとして用いる方法である．弱毒生ワクチンとは異なり生きていない（感染性がない）ため，一般的に弱毒生ワクチンよりも安全性は高いとされているが，一方生体内での増殖がみられないため，ワクチン効果は一般的に弱毒生ワクチンよりも弱いことが多い．また後に述べるように全粒子/全菌体ワクチンには生体の自然免疫を活性化する内在性アジュバントとして働く核酸や細胞壁由来成分も含まれるため，それらによる自然免疫を介した炎症反応によって，発熱や接種局所の発赤・腫脹がみられることも多い．季節性インフルエンザワクチンも国内では1972年までは全粒子型が使われていたが，その後，発熱などの副反応を低減する目的で現在も用いられているスプリット型に変更された．現在使

用されている一部のワクチン(A型肝炎，日本脳炎など)は全粒子型である(表1参照).

コンポーネントワクチンは，一度化学的に不活化した病原微生物をさらに破砕して，ワクチン抗原として有効な特定の成分を濃縮・精製したもので，近年では病原微生物から精製するのではなく，病原微生物由来の蛋白質を分子生物学的手法を用いて生産したリコンビナント蛋白質をワクチン抗原として用いることもある．全粒子/全菌体ワクチンに含まれていた内在性アジュバント物質はほぼ除かれているため，ワクチンによる発熱や接種局所の発赤・腫脹はほとんどみられず，一般的な安全性は弱毒生ワクチンや全粒子/全菌体ワクチンに比べて高いが，獲得免疫を誘導するために必要な自然免疫反応も弱まることが多く，ワクチン効果はその他のワクチンに比べて弱いといわざるを得ない．しかしながら，公衆衛生環境の改善に伴い，以前は許容されていたワクチン接種に伴う副反応を含めたリスクとワクチン接種を受けることで享受するベネフィットのバランスが変化しつつあり，より理論的な安全性と有効性の比が高いと考えられるコンポーネントワクチン型を選択したワクチンが増える傾向にある．さらに近年開発された多くのコンポーネントワクチンには，ワクチン効果を増強するために外来性のアジュバントを加えることが増えている(表1，表5参照).

このような現在のワクチンの特徴をふまえて，次世代ワクチンを考えた場合，最も重要なことは，後に詳しく述べるワクチンを構成する3要素である抗原，アジュバント，デリバリーシステムのすべてが，科学的な研究によって明らかとなっていて，かつそれらの効果や生体反応，さらには副反応も含めて予測可能であることだといえる．このきわめて高い予測可能性が担保されれば，次世代ワクチンはどのような型であってもよいと考えられ，水痘ワクチンをベースとした多価弱毒生ワクチン[7]，人工的なウイルス様粒子(VLP)[8]やDNAワクチン，リポソームやPLGAなどのナノパーティクル技術を応用したワクチンの開発[9]も進んでいる.

V. 自然感染とワクチン免疫の違い

自然感染とそれに対する宿主免疫応答の研究が現在の微生物学および免疫学の発展に大きく寄与しているように，自然感染に対する獲得防御免疫誘導のしくみを巧みに利用することはよりよいワクチンの開発に重要な知見となり得る．自然感染とワクチンによる免疫誘導のしくみの概略を図1に示す.

自然感染では感染に伴う病原体の増殖によって，例えばインフルエンザウイルスによる気道上皮の障害などの組織障害が起こり，それに伴いDAMPs(Damage associated molecular patterns)と総称される宿主組織や細胞由来の内在性自然免疫レセプター活性化物質(DNA，RNA，ATP，Uric acid，HMGB1など)が放出されることで自然免疫レセプター(表6参照)が活性化する[10]．またウイルス，細菌，真菌，寄生虫などの病原体は，それ自身がPAMPs(Pathogen associated molecular patterns)と総称される内在性の自然免疫レセプター活性化物質をもっており，それによっても宿主の自然免疫応答が誘導される[11]．これらによって誘導された自然免疫応答はいわゆる炎症反応を惹起し，またIL-1，IL-6，TNFα，



図1　自然感染とワクチンによる免疫誘導の比較
PAMPs：Pathogen associated molecular patterns, DAMPs：Damage associated molecular patterns.

1型インターフェロンなどによって全身性の発熱や倦怠感などが引き起こされる．宿主にとってはこのような反応は一見よくないことのようにみえるが，感染病原体に対する獲得免疫応答の誘導にはこれらの自然免疫応答が重要であることが近年の研究より明らかとなっている．感染によって成立した獲得免疫は，大きく液性免疫と細胞性免疫に分けられ，液性免疫としては，ウイルスなどに対する中和抗体や，細菌や真菌に対するオプソニン化抗体の誘導などがあげられる．細胞性免疫としては，細菌や真菌に対してのCD4T細胞からのIFN-γ産生による貪食細胞の活性化や，ウイルス感染細胞を直接排除する細胞障害性CD8T細胞（CTL）があげられる．これらの獲得免疫応答は，一次的な感染の収束に寄与するだけでなく，長期間にわたって免疫学的記憶として維持されるため，多くの病原体に対しては一度感染すると二度と感染しない「二度なし」と呼ばれる「免疫」が維持される．

ワクチン（特に不活化コンポーネントワクチン）による免疫誘導では，ワクチンそのものによる組織障害はほとんどなく，内在性の自然免疫レセプターを活性化しうるリガンドも含まれていないことが多いため，コンポーネントワクチンの抗原単独免疫では，宿主の自然免疫応答を惹起することができず，それまでに一度もその抗原に曝露されたことがないナイーブな宿主では獲得免疫応答は誘導されず，ワクチンに期待される免疫効果はほとんど賦与されない（図1）．ただし例外的にワクチン接種を受ける宿主がすでにその抗原に曝露されたことがありかつその抗原に対して免疫記憶が成立していた場合には，自然免疫応答がなくても，抗原刺激のみで記憶B細胞や記憶T細胞の再活性化が可能で，ワクチンによるブースト効果を得ることができる．現在使用されている季節性インフルエンザワクチンはスプリットHAワクチンと呼ばれ，高度に精製されたインフルエンザウイルスのHAやNA蛋白からなり，インフルエンザウイルスの内在性アジュバントとして働くウイルスゲノムRNAをほとんど含んでいないため，まだ一度もインフルエンザウイルスに感染したことのない乳幼児に対する効果は限定的であるが，すでにインフルエンザウイルスに顕性・不顕性を問わず感染したことのある学生や成人であればすでに存在している記憶免疫をブーストすることが可能である[12, 13]．

インフルエンザワクチンのように毎年接種しなければならないワクチンはむしろ例外的で多くのワクチンは自然感染が起こる前の乳

表5　臨床使用されているアジュバント

アジュバント名	主要な成分	使用されているワクチン	自然免疫受容体・シグナル分子	誘導される獲得免疫
アルミニウム	アルミニウム塩	B型肝炎ワクチン， 破傷風，DT，DTP，DTP-IPV 肺炎球菌ワクチン(PCV7) 子宮頸がんワクチン(ガーダシル®；MSD)	Syk→MAPK→PGE2 DNA (ref.15, 16) 不明	抗体，Th2
AS04	AIOH3＋MPL(3-O-desacyl-4'-monophosphoryl lipid A)	子宮頸がんワクチン(サーバリックス®；GSK)	MPL→TLR4→TRIF(ref.17) 不明	抗体，Th1/Th2
MF59	スクワレン(oil-in-water emulsion)	H1N1インフルエンザワクチン(CELTURA®；ノバルティス)*	MyD88(?)，ATP(?)(ref.14) 不明	抗体，Th2
AS03	スクワレン＋DL-α-トコフェロール(oil-in-water emulsion)	H1N1インフルエンザワクチン(アレパンリックス®；GSK)*	不明(ref.28)	抗体，Th2

＊特例承認

幼児に接種されることが多いため，近年開発された多くの不活化ワクチンには宿主の自然免疫応答を惹起するために外来性のアジュバントが加えられている．現在臨床使用されているアジュバント(表5)はalumと呼ばれるアルミニウム塩と，スクワレンを主体としたoil-in-waterのエマルジョン(AS03[28]やMF59[14])であり，これらのアジュバントを投与した部位には炎症性細胞の浸潤を伴う炎症反応がみられるため，何らかのDAMPsによって自然免疫レセプターが活性化し，獲得免疫応答につながっていると考えられている．実際にalumの場合には，組織障害で放出される宿主DNAがそのアジュバント効果に寄与することが報告されている[15, 16]．また臨床使用されているPAMPs型のアジュバントとしてはAS04[17]に含まれるMPL(TLR4の人工リガンド)が唯一であるが，その他のTLRリガンドもワクチンアジュバントとしての臨床使用に向けた臨床試験が進行中である[18]．このようにコンポーネントワクチンに加えられた外来性アジュバントは，自然感染でみられるPAMPsやDAMPsによる自然免疫応答を模倣するように，人工的なPAMPsやDAMPs誘導を起こす役割を果たしており，それらによる自然免疫応答を通して，量的に獲得免疫応答を誘導することはもちろん，惹起する自然免疫応答の種類に応じて獲得免疫応答を方向づけする役割を果たしている．このようにワクチンによる免疫誘導では抗原と外来性アジュバントを組合わせることで自然感染でみられる自然免疫応答から獲得免疫応答への流れを再現している．また一般的に自然感染で起こる発熱や組織障害に比べてワクチンで惹起される自然免疫応答に依存した副反応は軽微であると考えられるが，アジュバント添加によって生体の免疫反応は増強するため，むやみに理由なくアジュバントを添加するのではなく，アジュバント添加の必要性については慎重に熟慮したうえで判断されるべきである．

Ⅵ．ワクチンによる獲得免疫誘導

ワクチンの目的は，ワクチン抗原に対するT細胞およびB細胞応答を効率よく誘導し，かつ接種者に対して感染時に受けるようなダメージを与えないことである．ワクチンによるT細胞応答誘導には，抗原およびアジュバントを適切な抗原提示細胞にデリバリーすることが重要である(図2)．これまでの研究では，抗原提示細胞の中でも特に樹状細胞がT細胞分化(Th1，Th2，Th17，CTL)に重要であることが明らかとなっている．アジュバントによる樹状細胞に存在する自然免疫レセプターの活性化によって，取り込まれた蛋白抗原のプロセシングが促進されMHCによって提示されやすくなり(signal-1)，またCD80/86などの補助刺激分子の発現も増加すること(signal-2)で，T細胞応答が惹起される．また後に述べるように，樹状細胞サブセットやアジュバントの種類によってサイトカイン産生が異なること(signal-3)でT細胞分化が確定すると考えられている．誘導